- 24-month analysis indicated AGTC-501 was generally safe and well-tolerated, with no clinically significant safety events associated with treatment
- Data demonstrates the durable profile of AGTC-501, with the higher dose cohort showing a 57% response rate in the 24-month analysis of retinal sensitivity, the primary endpoint for the trial
- Benefit-risk profile supports on-going clinical development for the treatment of patients with X-Linked Retinitis Pigmentosa (XLRP) caused by retinitis pigmentosa GTPase regulator (RPGR) gene mutations
- Pivotal Phase 2/3 VISTA and open-label Phase 2 DAWN trials for AGTC-501 in XLRP are currently enrolling
, /PRNewswire/ — Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading ophthalmic gene therapy company with a purpose to save and restore the vision of patients with blinding retinal diseases, today announced the presentation of 24-month interim safety and efficacy results of the Phase 2 SKYLINE trial in patients with XLRP at the American Academy of Ophthalmology’s …